“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” Pfizer Chairman and CEO Dr. Albert Bourla told reporters on Monday.
Loncar added that Moderna’s stock will most likely stay stable even if their vaccine’s effectiveness rate is less than that of Pfizer-BioNTech. “It’ll still go up if the number is real close [to Pfizer’s], he explained. “But if it is significantly lower than that, then I do think it could be a problem.”
While Pfizer has touted their effectiveness rates, it is worth mentioning that the data is only preliminary and the vaccine itself still needs approval from necessary regulatory authorities. Moderna will be forced to undergo the same stringent oversight process.
—————————————-
Have a story you want USA Herald to cover? Submit a tip here and if we think it’s newsworthy, we’ll follow up on it.
